Recently, SDIC Juli completed a strategic equity investment in Abiochem Biotechnology Co., Ltd. (hereinafter referred to as “Abiochem”), a leading domestic biomanufacturing enterprise, with a joint investment of RMB 450 million by the Juli M&A Fund and the Juli Hangshi Fund.

Abiochem has established a comprehensive bioengineering resource library (comprising enzymes, genetic elements, and chassis cells) and a synthetic biology technology innovation platform. The company has accumulated extensive experience in biosynthesis, the design and creation of high-performance cell factories, and the scaled production of products. Abiochem possesses a complete synthetic biology technological pathway and industrialization capability spanning “enzymes–biosynthetic pathways–intelligent cells–product creation.” With a diverse product portfolio, Abiochem has become a strategic partner to many industry giants, maintaining a leading advantage in the biopharmaceuticals and green agriculture sectors. In recent years, the company has achieved continuous breakthroughs in the nutrition and health field, with functional food ingredients such as Human Milk Oligosaccharides (HMOs), steviol glycosides, and sialic acid (N-acetylneuraminic acid) being the first in China to receive regulatory approval.

To implement SDIC Group’s strategic deployment in developing the biomanufacturing industry, SDIC Juli has continued to invest in the biomanufacturing sector. This investment marks another platform enterprise in biomanufacturing added to its portfolio, following Mu’en Biotechnology. Going forward, SDIC Juli will engage in comprehensive cooperation with Abiochem Biotechnology Co., Ltd. in areas such as biomanufacturing innovation platforms, application R&D centers, non-grain feedstock research and development, and fund investments. These efforts aim to further consolidate Abiochem’s leading position in the biomanufacturing field and generate sustained economic and social benefits for all investors.